Read by QxMD icon Read

Fecal calprotectin

Francesca Palone, Roberta Vitali, Salvatore Cucchiara, Maurizio Mennini, Alessandro Armuzzi, Daniela Pugliese, Renata DʼIncà, Brigida Barberio, Laura Stronati
BACKGROUND: Fecal high mobility group box 1 (HMGB1) has been suggested to be a novel noninvasive biomarker of gut inflammation. We aimed to assess the reliability of fecal HMGB1, compared with fecal calprotectin (FC), in detecting intestinal inflammation in pediatric and adult patients with inflammatory bowel disease (IBD) and to evaluate the accuracy of HMGB1 in identifying patients with IBD in clinical and endoscopic remission who still have histologic features of inflammation. METHODS: Stool samples from 85 children with IBD (49 Crohn's disease [CD] and 36 ulcerative colitis [UC] and 119 adults [57 Crohn's disease and 62 ulcerative colitis]) were analyzed for the study...
October 13, 2016: Inflammatory Bowel Diseases
Mara de Moura Gondim Prata, A Havt, D T Bolick, R Pinkerton, Aam Lima, R L Guerrant
Fecal biomarkers have emerged as important tools to assess intestinal inflammation and enteropathy. The aim of this study was to investigate the correlations between the fecal markers, myeloperoxidase (MPO), lactoferrin (FL), calprotectin (FC) and lipocalin-2 (Lcn-2), and to compare differences by breastfeeding status as well as normalization by fecal protein or by fecal weight. Simultaneous, quantitative MPO, FL, FC and Lcn-2, levels were determined in frozen fecal specimens collected from 78 children (mean age 15...
2016: Journal of Translational Science
Vahid Basirat, Zahra Azizi, Sanam Javid Anbardan, Mina Taghizadeh Asl, Yasaman Farbod, Azam Teimouri, Nasser Ebrahimi Daryani
INTRODUCTION Due to limitation of colonoscopy in assessing the entire bowel and patients' intolerance in inflammatory bowel disease (IBD), in the current study, we aimed to prospectively compare the accuracy of (99m)Tc(V)-dimercaptosuccinic acid (DMSA) and fecal calprotectin with ileocolonoscopy as new methods for localizing inflammations. METHODS Current prospective study conducted between 2012 and 2014 on 30 patients with IBD attending Gastroenterology Clinic of Tehran University of Medical Sciences. Fecal calprotectin and disease activity were measured for all participants and all of them underwent (99m)Tc (V)-DMSA scintigraphy and colonoscopy...
July 2016: Middle East Journal of Digestive Diseases
Anna Winberg, Olga Nagaeva, Ivan Nagaev, Catarina Lundell, Ignacio Arencibia, Lucia Mincheva-Nilsson, Eva Rönmark, Christina E West
BACKGROUND: There is need for prognostic markers for symptomatic food allergy since current diagnostic methods are insufficient and/or time and labor consuming. OBJECTIVE: To estimate the cytokine mRNA profiles in peripheral blood mononuclear cells (PBMC) before and after a double-blind placebo-controlled food challenge series in schoolchildren with suspected allergy to milk, egg or cod and in healthy controls. Analyses of fecal inflammatory biomarkers before and after the challenge were included...
December 2016: Cytokine
Shunsuke Sekiya, Makoto Murata, Satoshi Arai, Hiroshi Murayama, Atushi Kawasaki, Noriyuki Ashida, Kohki Okada, Masaki Ikemoto
Calprotectin, a heterodimer of S100A8 and S100A9, has been reported to be a useful biomarker in inflammatory bowel disease (IBD); however, the relationship between the fecal level of S100A9 and the extent of inflammation in IBD remains unclear. Our aim was to develop a new enzyme-linked immunosorbent assay (ELISA) for rat S100A9, and to investigate whether changes in fecal S100A9 levels reflect the inflammatory conditions in the intestinal tracts of rats with dextran sulfate sodium (DSS)-induced colitis. Anti-rat S100A9 monoclonal antibodies were raised in mice and used for the development of a novel ELISA for rat S100A9...
September 28, 2016: Journal of Immunological Methods
Anne-Claire Frin, Jérôme Filippi, Gilles Boschetti, Bernard Flourie, Jocelyne Drai, Patricia Ferrari, Xavier Hebuterne, Stéphane Nancey
BACKGROUND: Fecal markers might predict the response to anti-TNFα in ulcerative colitis (UC). AIMS: To compare the performance of fecal calprotectin (fCal), lactoferrin (fLact), M2-PK (fM2-PK), neopterin (fNeo), and zonulin (fZon) to predict the response to therapy in active UC patients. METHODS: Disease activity from 31 consecutive patients with an active UC, treated with infliximab (IFX) was assessed by the Mayo score at baseline and at week 14 and by the partial Mayo score at W52 and stool samples collected for fecal marker measurements at W0, W2, and W14...
September 13, 2016: Digestive and Liver Disease
Greg Rosenfeld, Astrid-Jane Greenup, Andrew Round, Oliver Takach, Lawrence Halparin, Abid Saadeddin, Jin Kee Ho, Terry Lee, Robert Enns, Brian Bressler
AIM: To evaluate the perspective of gastroenterologists regarding the impact of fecal calprotectin (FC) on the management of patients with inflammatory bowel disease (IBD). METHODS: Patients with known IBD or symptoms suggestive of IBD for whom the physician identified that FC would be clinically useful were recruited. Physicians completed an online "pre survey" outlining their rationale for the test. After receipt of the test results, the physicians completed an online "post survey" to portray their perceived impact of the test result on patient management...
September 28, 2016: World Journal of Gastroenterology: WJG
Hengameh C Mirsepasi-Lauridsen, Sofie Ingdam Halkjaer, Esben Munk Mortensen, Magnus C Lydolph, Inge Nordgaard-Lassen, Karen Angeliki Krogfelt, Andreas Munk Petersen
E. coli of the phylogenetic group B2 harbouring Extra intestinal Pathogenic Escherichia coli (ExPEC) genes are frequently seen as colonizers of the intestine in patients with active ulcerative colitis (UC). In this study, we describe the influence of E. coli Nissle (EcN) B2 as add-on treatment to conventional therapies in patients with active UC. For this study one hundred active UC patients were randomized to ciprofloxacin or placebo for 1 week followed by EcN or placebo for 7 weeks. Stool samples were collected at weeks 0, 1, 8, 12, where E...
September 30, 2016: Scientific Reports
Alexandre Nuzzo, Magaly Zappa, Dominique Cazals-Hatem, Yoram Bouhnik
BACKGROUND: Mesenteric panniculitis (MP) is mostly an associated sign of an intra-abdominal or systemic inflammatory primary disease. Nevertheless, etiological and differential diagnosis of idiopathic MP can be challenging when an associate primary cause is not in the foreground. METHODS: We report here the case of an isolated small bowel Crohn's disease, long time considered as idiopathic MP. RESULTS: This patient presented to our department with a 10-year history of acute abdominal symptoms evolving with flare-up and remission...
September 2016: Medicine (Baltimore)
Youlian Zhou, Huiting Chen, Hanchang He, Yanlei Du, Jiaqi Hu, Yingfei Li, Yuyuan Li, Yongjian Zhou, Hong Wang, Ye Chen, Yuqiang Nie
This study was performed to investigate the relationship between the abundance of pathogenic gut microbes in Chinese patients with inflammatory bowel disease (IBD) and disease severity.We collected clinical data and fecal samples from 47 therapy-naive Chinese patients with ulcerative colitis (UC), 67 patients with Crohn disease (CD), and 48 healthy volunteers. Bacteria levels of Fusobacterium species (spp), enterotoxigenic Bacteroides fragilis (B fragilis), enteropathogenic Escherichia coli (E coli), and Enterococcus faecalis (E faecalis) were assessed by quantitative real-time PCR (qRT-PCR)...
September 2016: Medicine (Baltimore)
Ibrahim Hatemi, Gulen Hatemi, Aykut F Çelik
PURPOSE OF REVIEW: Gastrointestinal system can be involved in primary and secondary vasculitides. The recent data regarding the pathophysiology, clinical findings, diagnosis, management, and outcome of gastrointestinal involvement in different types of vasculitis are reviewed. RECENT FINDINGS: Diagnosis of gastrointestinal vasculitis may be difficult and relies mostly on imaging, because biopsy samples are hard to obtain and superficial mucosal biopsies have a low yield...
September 28, 2016: Current Opinion in Rheumatology
Chiara Rosso, Gian P Caviglia, Rinaldo Pellicano
Calprotectin is a heterodimeric protein which belongs to the calcium-binding protein S100 family. Calprotectin is released by leukocytes at the site of inflammation and it can be detected in the feces where it remains stable for about a week. Hence, increased fecal calprotectin (FC) levels are found in several inflammatory conditions, mainly the inflammatory bowel diseases (IBD). In the setting of pediatric gastroenterology, the importance of FC has increased over time. This review aims to summarize the most recent findings concerning the role of FC in the algorithm of different inflammatory and non-inflammatory conditions among pediatric patients...
December 2016: Minerva Pediatrica
Kirsten Risby, Steffen Husby, Niels Qvist, Marianne S Jakobsen
BACKGROUND: During the last decades neonatal outcomes for children born with gastroschisis have improved significantly. Survival rates >90% have been reported. Early prenatal diagnosis and increased survival enforce the need for valid data for long-term outcome in the pre- and postnatal counseling of parents with a child with gastroschisis. METHODS: Long-term follow-up on all newborns with gastroschisis at Odense University Hospital (OUH) from January 1 1997-December 31 2009...
September 2, 2016: Journal of Pediatric Surgery
Nicola de Bortoli, Leonardo Frazzoni, Edoardo V Savarino, Marzio Frazzoni, Irene Martinucci, Aleksandra Jania, Salvatore Tolone, Michele Scagliarini, Massimo Bellini, Elisa Marabotto, Manuele Furnari, Giorgia Bodini, Salvatore Russo, Lorenzo Bertani, Veronica Natali, Lorenzo Fuccio, Vincenzo Savarino, Corrado Blandizzi, Santino Marchi
OBJECTIVES: We aimed to evaluate the prevalence of irritable bowel syndrome (IBS) in patients with typical reflux symptoms as distinguished into gastroesophageal reflux disease (GERD), hypersensitive esophagus (HE), and functional heartburn (FH) by means of endoscopy and multichannel intraluminal impedance (MII)-pH monitoring. The secondary aim was to detect pathophysiological and clinical differences between different sub-groups of patients with heartburn. METHODS: Patients underwent a structured interview based on questionnaires for GERD, IBS, anxiety, and depression...
September 20, 2016: American Journal of Gastroenterology
Korinna Ulbricht, Peter Layer, Viola Andresen
Chronic, non-infectious diarrhea can be caused by a variety of gastrointestinal diseases. In anamnesis, it is important to take accompanying warning symptoms and specific triggers into account. The fecal inflammatory marker calprotectin may help differentiating between organic and functional gastrointestinal disorders, but it is not specific. Among other options, gelling fibres, Loperamide and Cholestyramine as well as probiotics are available for the symptomatic treatment of chronic diarrhea. For long-term treatment of chronic diarrhea with the enkephalinase inhibitor racecadotril, which is approved for acute diarrhea, only limited data are available...
September 2016: Deutsche Medizinische Wochenschrift
Burak Özşeker, Cem Şahin, Havva Solak Özşeker, S Cumali Efe, Taylan Kav, Yusuf Bayraktar
One of the regions of involvement of Behçet's disease (BD), a systematic inflammatory vasculitis with unknown etiology, is the gastrointestinal (GI) tract. Upper GI endoscopy, colonoscopy, and capsule endoscopy are frequently used methods to diagnose the intestinal involvement of BD. The aim of this study was to investigate the role of fecal calprotectin (FC) in the evaluation of intestinal involvement in BD. Material and Method. A total of 30 patients who were diagnosed with BD and had no GI symptoms and 25 individuals in the control group were included in this study...
2016: Disease Markers
Silje Thorsvik, Jan Kristian Damås, Atle van Beelen Granlund, Trude Helen Flo, Kåre Bergh, Ann Elisabet Østvik, Arne Kristian Sandvik
BACKGROUND AND AIM: Accurate, non-invasive biomarkers are needed to diagnose and monitor inflammatory bowel disease (IBD). Neutrophil Gelatinase Associated Lipocalin (NGAL), also known as Lipocalin 2, is expressed in inflamed colonic epithelium and neutrophilic granulocytes. This study explores its properties as a biomarker in feces and plasma and, for the first time, compares fecal NGAL systematically with the existing fecal biomarker calprotectin. METHODS: NGAL was measured in feces from 73 patients with IBD, 21 patients with infectious enterocolitis, 21 patients with irritable bowel syndrome (IBS) and 23 healthy subjects using ELISA...
September 18, 2016: Journal of Gastroenterology and Hepatology
Börje Jonefjäll, Lena Öhman, Magnus Simrén, Hans Strid
BACKGROUND: Gastrointestinal symptoms (GI) compatible with irritable bowel syndrome (IBS) are common in patients with ulcerative colitis (UC) in remission. The causes of these symptoms remain to be clarified. Our aim was to investigate prevalence and factors associated with IBS-like symptoms in patients with UC in deep remission. METHODS: We included 298 patients with UC and used Mayo score, sigmoidoscopy, and fecal calprotectin to define deep remission versus active disease...
November 2016: Inflammatory Bowel Diseases
Tom Nilsen, Kathrin Sunde, Lars-Olof Hansson, Aleksandra Mandic Havelka, Anders Larsson
BACKGROUND: Fecal calprotectin assays are widely used to exclude inflammatory bowel disease (IBD) in patients with suspected IBD. A problem with the fecal calprotectin assays is the rather long test-turnaround times. A particle enhanced turbidimetric immunoassays (PETIA) for fecal calprotectin would reduce test-turnaround times and would permit more laboratories to perform the measurements. The aim of this study was to evaluate a new feces calprotectin PETIA. METHOD: Using routine fecal samples the feces calprotectin PETIA was validated on two chemistry analyzers, Mindray BS-380 and Cobas 501...
September 15, 2016: Journal of Clinical Laboratory Analysis
Marjorie M Walker
Chronic and complex gut syndromes are complex to diagnose and manage, but good clinicopathologic correlation, recognition of new entities, understanding (and understanding the limits) of genetic susceptibility and the importance of the microbiome, dysbiosis and influence of the environmental allows development of new models for diagnosis. An awareness of overlap in chronic gut syndromes has been clarified by the realization that inflammatory pathways involved in chronic gut disease can arise through variable gene expression that is influenced by the environment in susceptible individuals...
October 2016: Journal of Clinical Gastroenterology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"